Jump to content

Translational Genomics Research Institute

Coordinates: 33°27′10.68″N 112°4′1.83″W / 33.4529667°N 112.0671750°W / 33.4529667; -112.0671750
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Rawderikich86 (talk | contribs) at 14:28, 11 July 2023 (History and activities). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

33°27′10.68″N 112°4′1.83″W / 33.4529667°N 112.0671750°W / 33.4529667; -112.0671750

Translational Genomics Research Institute
Company typeResearch Institute
IndustryGenomics
FoundedJuly 2002, Phoenix, Arizona, United States
HeadquartersPhoenix, Arizona, United States
Key people
Jeffrey Trent
Revenue
  • Increase$51.7 million (2007)[1]
  • $18.3 million (2003)[1]
Number of employees
258 (2008)[1]
Websitewww.tgen.org
File:TGEN.jpg
The Translational Genomics Research Institute at night

The Translational Genomics Research Institute (TGen) is a non-profit genomics research institute based in Arizona, United States.

The Translational Genomics Research Institute (TGen) is a non-profit genomics research institute based in Phoenix, Arizona, United States.

History and activities

TGen was established in July 2002 by Jeffrey Trent in Phoenix, Arizona, with an initial investment of US$100 million from Arizona public and private-sector investors.[1]

TGen conducts research on various human disorders, including Alzheimer's disease, autism, Parkinson's, diabetes, cancer, and other complex diseases. The institute focuses on translational genomics research, which aims to apply the findings of the Humane Genome Project to develop improved diagnostics, prognostics, and therapies for these diseases.

The field of translational genomics research searches for ways to apply results from the Human Genome Project to the development of improved diagnostics, prognostics, and therapies for cancer, neurological disorders, diabetes and other complex diseases.

TGen has contributed to the growth of scientific research and biotechnology in Arizona. The institute has been involved in collaborations and studies, such as the research on chronic traumatic encephalopathy (CTE) in former NFL players in partnership with Exosome Sciences.

TGen Administration

  • Jeffrey M. Trent, Ph.D., President & Scientific Director[1]
  • Sunil Sharma, MD FACP, Deputy Director
  • Michael Bassoff, President, TGen Foundation
  • Daniel Von Hoff, M.D., F.A.C.P., Executive Vice President, Physician-in-Chief[2]
  • Tess Burleson, MBA, CPA, Chief Operating Officer and President, TGen Accelerators
  • Chuck Coleson, Chief Financial Officer
  • Galen Perry, Vice President, Marketing and Communications
  • Brady Young, Vice President, Human Resources
  • Kendall Van Keuren-Jensen, co-Director[3]

References

  1. ^ a b c d e Alltucker, Ken (16 April 2008). "5-year-old TGen fights for funding". The Arizona Republic. Archived from the original on 17 January 2013.
  2. ^ Alltucker, Ken (16 April 2008). "Cancer-drug trials show promise". The Arizona Republic. Archived from the original on 17 January 2013.
  3. ^ "Exosome Sciences, TGen to Launch Study of CTE in Former NFL Players". CellOMICs. 26 March 2018. Retrieved 27 March 2018.